← back to search

Ibrahim Yakoub‐Agha

Inserm · FR
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and Chronic Myeloid Leukemia Treatments.
h-index
75
citations
26,186
works
1,033
NIH funding
primary concept
Medicine
email

Recent publications

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Blood 2025cited by 16position: middledoi
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Journal of Clinical Oncology 2025cited by 7position: middledoi
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
The Lancet Oncology 2025cited by 6position: middledoi
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
Bone Marrow Transplantation 2025cited by 6position: middledoi
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
Bone Marrow Transplantation 2025cited by 5position: middledoi
Management of liver sinusoidal obstruction syndrome/veno-occlusive disease in adults: a 2025 perspective from an international expert group
Bone Marrow Transplantation 2025cited by 5position: middledoi
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party
Bone Marrow Transplantation 2025cited by 3position: middledoi
Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
HemaSphere 2025cited by 3position: middledoi
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplantation and Cellular Therapy 2025cited by 3position: middledoi
Pneumonia definition in allogeneic hematopoietic cell transplant recipients: Update and challenges in 2024. Recommendations from the EBMT Infectious Diseases Working Party and Practice Harmonization and Guidelines committee
Current Research in Translational Medicine 2025cited by 2position: middledoi
Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party
Bone Marrow Transplantation 2025cited by 1position: middledoi
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
EClinicalMedicine 2024cited by 77position: middledoi
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
Blood Advances 2024cited by 57position: middledoi
Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies
Journal of Clinical Oncology 2024cited by 37position: middledoi
5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Blood 2024cited by 14position: middledoi
Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor <scp>AML</scp> patients in <scp>CR2</scp>: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
American Journal of Hematology 2024cited by 11position: middledoi
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Leukemia 2024cited by 10position: middledoi
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison
Bone Marrow Transplantation 2024cited by 9position: middledoi
Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation 2024cited by 8position: middledoi
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation
Bone Marrow Transplantation 2024cited by 4position: middledoi
HLA Mismatching and Transplant Outcome in the Ptcy Era: A Comprehensive Study By the EBMT Cellular Therapy and Immunobiology Working Party
Transplantation and Cellular Therapy 2024cited by 3position: middledoi
Pitfalls in definitions on respiratory viruses and particularities of Adenovirus infection in hematopoietic cell transplantation patients: Recommendations from the EBMT practice harmonization and guidelines committee
Current Research in Translational Medicine 2024cited by 2position: middledoi
An international survey to better understand the current incidence, severity, and management of VOD/SOS
Bone Marrow Transplantation 2024cited by 2position: middledoi
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Blood 2023cited by 289position: lastdoi
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
Blood 2023cited by 135position: middledoi
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)
Bone Marrow Transplantation 2023cited by 102position: middledoi
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
Journal of Clinical Oncology 2023cited by 51position: middledoi
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy
Bone Marrow Transplantation 2023cited by 32position: firstdoi
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
The Lancet Haematology 2023cited by 24position: middledoi
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
Leukemia 2023cited by 22position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mohamad Mohty · Inserm26 papers (2012–2025)Nicolaus Kröger · Universität Ulm19 papers (2014–2025)Arnon Nagler · University of Naples Federico II13 papers (2015–2025)Myriam Labopin · Inserm12 papers (2012–2024)Didier Blaise · Institut Pprime11 papers (2015–2025)Jürgen Finke · University of Education Freiburg11 papers (2014–2023)Rafael F. Duarte · Hospital Universitario Puerta de Hierro Majadahonda10 papers (2019–2024)Selim Corbacioglu · University of Regensburg10 papers (2019–2024)Régis Peffault de Latour · Heinrich Heine University Düsseldorf10 papers (2015–2023)John A. Snowden · Sheffield Teaching Hospitals NHS Foundation Trust10 papers (2019–2025)Jakob Passweg · Centre Hospitalier Universitaire de Nantes9 papers (2015–2025)Dietrich W. Beelen · West German Heart and Vascular Center Essen9 papers (2017–2024)Grzegorz Basak · Medical University of Warsaw8 papers (2019–2022)Christian Chabannon · Institut Pprime8 papers (2019–2022)Jan Styczyński · Nicolaus Copernicus University8 papers (2019–2025)Gèrard Socié · Institut de Psychiatrie et Neurosciences de Paris8 papers (2013–2025)Fabio Ciceri · Vita-Salute San Raffaele University8 papers (2020–2025)Zinaida Perić · European Society for Blood and Marrow Transplantation7 papers (2020–2025)Arjan C. Lankester · Leiden University7 papers (2019–2022)Annalisa Ruggeri · European Organisation for Rare Diseases7 papers (2015–2025)